← Back to Search

Behavioural Intervention

Cognitive Rehabilitation Program for Intellectual Disability

N/A
Recruiting
Led By Young Shin Kim, MD PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Children aged 4-8 years (48-96 months) of both genders at the time of obtaining consent.
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week 0), follow-up (week 16)

Summary

This trial tests a special program with fun games on tablets to help children with mild intellectual disabilities improve their thinking skills. The program aims to make their brains work better through consistent game play.

Who is the study for?
This trial is for children aged 4-8 with borderline intellectual functioning or mild intellectual disability. They must be able to communicate and participate in tests and activities, and their legal guardians must consent. Children who can't see, hear well, or have been in another drug trial recently can't join.
What is being tested?
The study examines a computerized cognitive rehabilitation program (D-kit/EF1) used on an iOS device versus a sham group watching educational videos. Kids will use the program or watch videos five times a week for 30 minutes over 12 weeks.
What are the potential side effects?
Since this trial involves cognitive training using digital devices, side effects might include eye strain, headache from screen exposure, or frustration if tasks are challenging. However, specific side effects of D-kit/EF1 aren't detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My child is between 4 and 8 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week 0), follow-up (week 16)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week 0), follow-up (week 16) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in NIHTB-CB DCCS Computed Score from Baseline to Week 12
Secondary study objectives
Change in BRIEF-P or BRIEF-2 Global Executive Composite Score from Baseline to Week 12
Change in BRIEF-P or BRIEF-2 Global Executive Composite Score from Baseline to Week 16
Change in NIHTB-CB DCCS Computed Score from Baseline to Week 16
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: D-kit/EF1 groupExperimental Treatment1 Intervention
The experimental group will use the D-kit/EF1 program on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks. The program will be performed under the supervision of the participant's parents or primary caregivers, following the provided program usage guide.
Group II: Sham groupPlacebo Group1 Intervention
The sham group will watch an educational animation video on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks. The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided. The educational animations are original animations created by DOBAIN Inc..

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cognitive rehabilitation for Intellectual Disability (ID) often involves structured programs designed to improve cognitive functions such as memory, attention, and problem-solving skills. These programs, like the D-kit/EF1, typically use repetitive, task-specific training to enhance neural plasticity and cognitive performance. The mechanisms of action include strengthening neural connections and promoting the development of new neural pathways through consistent practice and engagement in cognitive tasks. This is crucial for ID patients as it can lead to improved daily functioning, greater independence, and enhanced quality of life by addressing specific cognitive deficits and enabling better adaptation to everyday challenges.
The Clinical Trials Mosaic: Toward a Range of Clinical Trials Designs to Optimize Evidence-Based Treatment.Evaluation of a group based cognitive behavioural therapy programme for menstrual pain management in young women with intellectual disabilities: protocol for a mixed methods controlled clinical trial.

Find a Location

Who is running the clinical trial?

DoBrain Inc.Industry Sponsor
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,870 Total Patients Enrolled
3 Trials studying Intellectual Disability
824 Patients Enrolled for Intellectual Disability
Young Shin Kim, MD PhDPrincipal InvestigatorUniversity of California, San Francisco

Media Library

D-kit/EF1 (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05933005 — N/A
Intellectual Disability Research Study Groups: D-kit/EF1 group, Sham group
Intellectual Disability Clinical Trial 2023: D-kit/EF1 Highlights & Side Effects. Trial Name: NCT05933005 — N/A
D-kit/EF1 (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05933005 — N/A
~34 spots leftby Dec 2025